products was significantly higher (greater than 2-fold) than the morphologic mast cell counts, which suggested the presence of KIT mutation in non-mast cell components. Table 1 summarizes the demographics, BM myeloid cell counts, KIT mutation levels and final disease classification. Review of clinical features and pathological material revealed coexisting AHNMCD in all five discordant cases. Among the remaining 11 cases in which percentage of mutated KIT PCR product was roughly equal to or less than the number of mast cells, three had associated mild eosinophilia, two had associated CMML and the rest were morphologically consistent with pure MCDs. There was striking female predominance among the pure MCD and MCD with isolated eosinophilia cases (9 of 10) compared to the male predominance in MCD with AHNMCD cases (6/6 male, Po 0.002). For all 39 patients in the study, KIT mutation was detected much more frequently in MCD with ANMHD compared with those cases in which KIT mutation was not detected by either pyrosequencing or D816V qPCR (1/26, 1 CMML).
Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome Leukemia (2007) Lenalidomide (Revlimid, Celgene) is an immunomodulatory agent with both erythropoetic and cytogenetic remitting activity in patients with primary myelodysplastic syndrome (MDS) associated with interstitial deletion of chromosome 5q. MDS secondary to chemotherapy or ionizing radiation is historically associated with an aggressive natural history and unfavorable prognosis with resistance to standard therapeutic agents. 1 Here we report two patients with secondary MDS and deletion 5q who achieved hematologic or cytogenetic responses following treatment with lenalidomide.
In the first case, a seventy-four-year-old male with secondary MDS was initially diagnosed in June 1999 with adenocarcinoma of the gastroesophageal junction. He underwent esophagectomy with gastric pull through and surgical staging of T3 N1 M0 disease (six of nine lymph nodes involved). He received 45 Gy post-operative radiotherapy and aggressive local regional extracorporeal perfusional chemotherapy with mitomycin-C, interleukin-2, epirubicin, etoposide, 5-fluorouracil, leucovorin and methotrexate. He has remained in a sustained complete remission from the adenocarcinoma. However, he developed mild thrombocytopenia in 2001, followed by progressive anemia and thrombocytopenia in early 2006. By February 2006, he had a hemoglobin level of 8.8 g/dl with a white blood cell count of 2400/ml and platelet count of 54 000/l. Bone marrow aspirate and biopsy were performed in March 2003 demonstrating a relatively hypocellular marrow with trilineage dysplasia and a myeloid/erythroid ratio of 1:1.2. The myeloblast count was 15% with rare ringed sideroblasts and cytogenetic studies demonstrated a 5q 13-33 deletion in 20 of 23 metaphases analyzed. He initially received treatment with recombinant erythropoietin 10 000 units three times a week without improvement and was dependent on red blood cell transfusion. A repeat bone marrow biopsy performed in April 2006 showed no change in medullary blast percentage (16%) or karyotype. The patient started treatment with lenalidomide at a dose of 10 mg daily in June 2006. He received treatment for 10 consecutive days followed by a 7-day treatment hiatus for pruritic rash before resuming lenalidomide at 5 mg daily dose. After 2 months of treatment, he experienced a progressive rise in hemoglobin level (44 g/dl increase) and moderate improvement in platelet count (Table 1) Peripheral blood stem cells were mobilized with AMD3100 and granulocyte colony-stimulating factor. On 16 July 2005, he underwent a conditioning regimen with cyclophosphamide and a total body irradiation followed by autologous stem cell rescue. He engrafted promptly, however, thrombocytopenia persisted at both 100 and 180 days after the procedure. A bone marrow evaluation performed on February 2006 was highly suspicious for MDS. A repeat bone marrow evaluation on May 2006 revealed dyserythropoiesis, dysmegakaryopoiesis with no increase in myeloblasts, and a complex karyotype with the following cytogenetic abnormalities: del(5q), À7, 12pÀ and À20.
As summarized in Table 2 , the patient's platelet count started to decline in July 2006 and treatment with lenalidomide 10 mg daily was initiated on 20 July 2006. His baseline white blood cell count was 3000/ml, hemoglobin level of 10.4 g/dl and platelet count 82 000/ml. Lenalidomide was continued for 30 days, during which time the platelet count after an initial drop recovered to over 100 000/ml for the first time in 5 months.
Lenalidomide has proven efficacy in the treatment of primary MDS and was approved by the Food and Drug Administration (FDA) in the United States in December 2005 for the treatment of transfusion-dependent, low or intermediate-1 risk MDS with chromosome 5q deletion. Approximately 70% of patients with MDS and deletion 5q as the sole chromosomal abnormality treated on the MDS-001 and MDS-003 trials achieved major hematologic and cytogenetic response. 2, 3 Response rates in patients with complex karyotype, which is characteristic of treatment-induced MDS, was not significantly different from patients with an isolated 5q deletion. The presence of one or more chromosomal abnormalities portends a more unfavorable prognosis in MDS with deletion 5q. However, in the MDS-003 trial, overall survival showed no significant difference when analyzed by karyotype complexity, suggesting that lenalidomide may alter the natural history of this disease in higher risk patients.
Patients with treatment-related MDS were excluded from both the MDS-001 and MDS-003 trials. To our knowledge, this is the first report of response to lenalidomide treatment in secondary MDS. This letter describes one patient with secondary MDS who Letters to the Editor achieved morphologic and cytogenetic remission after 2 months of treatment with lenalidomide therapy and a second patient who achieved a platelet response after only 1 month of therapy before receiving an unrelated allogeneic stem cell transplant. Both patients remain without any evidence of relapse with a maximum follow-up of 8 months.
Both radiation therapy and traditional DNA-interactive antineoplastics, such as alkylating agents and topoisomerase II inhibitors, are known genotoxins with the potential to induce MDS or acute myeloid leukemia (AML) that commonly harbors a chromosome 5q deletion with high frequency of evolution to AML and short overall survival. [4] [5] [6] Our findings indicate that lenalidomide has therapeutic potential in patients with secondary MDS with complex karyotype accompanied by chromosome 5q deletion. 
